Wow. American College of Cardiology no longer recommending diet and exercise for weight loss, going straight to Ozempic.


The American College of Cardiology just released new guidance that flips the old playbook. For years, patients were told to try diet and exercise first, then consider medication if that failed. That sequence is now optional.

In its June 2025 clinical guidance, the ACC recommends that doctors can now consider weight loss drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) as first-line treatments for eligible patients. No more mandatory “try and fail” period with lifestyle changes

https://sciencex.com/wire-news/511880778/american-college-of-cardiology-issues-guidance-on-weight-managem.html

https://www.acc.org/About-ACC/Press-Releases/2025/06/20/14/11/American-College-of-Cardiology-Issues-Guidance-on-Weight-Management-Drugs

https://cardiovascularbusiness.com/topics/clinical/heart-health/american-college-cardiology-now-supports-early-use-medication-treat-obesity